S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price & News

+0.15 (+4.81%)
(As of 05/20/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
483,400 shs
Average Volume
522,189 shs
Market Capitalization
$164.79 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Rhythm Pharmaceuticals logo

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.


Rhythm Pharmaceuticals Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$3.15 million
Book Value
$4.68 per share


Net Income
$-69.61 million
Net Margins
Pretax Margin




Free Float
Market Cap
$164.79 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.95 out of 5 stars

Medical Sector

653rd out of 1,416 stocks

Pharmaceutical Preparations Industry

303rd out of 677 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

Is Rhythm Pharmaceuticals a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Rhythm Pharmaceuticals stock.
View analyst ratings for Rhythm Pharmaceuticals
or view top-rated stocks.

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Rhythm Pharmaceuticals

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Tuesday, May, 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by $0.07. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 55.66% and a negative net margin of 3,598.16%. During the same period in the previous year, the business earned $0.90 EPS.
View Rhythm Pharmaceuticals' earnings history

What price target have analysts set for RYTM?

8 analysts have issued 1-year price objectives for Rhythm Pharmaceuticals' shares. Their forecasts range from $9.00 to $45.00. On average, they expect Rhythm Pharmaceuticals' share price to reach $25.38 in the next year. This suggests a possible upside of 676.0% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rhythm Pharmaceuticals' key executives?
Rhythm Pharmaceuticals' management team includes the following people:
  • Dr. David P. Meeker M.D., Chairman, Pres & CEO (Age 68, Pay $836.08k)
  • Mr. Hunter C. Smith M.B.A., CFO & Treasurer (Age 53, Pay $692.84k)
  • Ms. Jennifer L. Chien, Exec. VP & Head of North America (Age 47, Pay $194.95k)
  • Mr. William T. Roberts, Chief Accounting Officer (Age 43)
  • Mr. Joseph Shulman, Chief Technical Officer
  • Mr. David Connolly, Head of Investor Relations & Corp. Communications
  • Mr. Jim Flaherty, Sr. VP & Gen. Counsel
  • Ms. Sarah Ryan, VP of Sales & Marketing
  • Ms. Pamela Cramer, Chief HR Officer
  • Mr. Yann Mazabraud, Exec. VP & Head of International (Age 49)
What is 's approval rating as Rhythm Pharmaceuticals' CEO?

1 employees have rated Rhythm Pharmaceuticals CEO on Glassdoor.com. has an approval rating of 100% among Rhythm Pharmaceuticals' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (12.49%), Federated Hermes Inc. (10.05%), Goldman Sachs Group Inc. (6.63%), BlackRock Inc. (6.52%), Vanguard Group Inc. (4.48%) and Rock Springs Capital Management LP (2.45%). Company insiders that own Rhythm Pharmaceuticals stock include David P Meeker, Hunter C Smith, Joseph Shulman, Nithya Desikan, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends for Rhythm Pharmaceuticals

Which major investors are selling Rhythm Pharmaceuticals stock?

RYTM stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, State Street Corp, Wellington Management Group LLP, Endurant Capital Management LP, Citigroup Inc., Vanguard Group Inc., BlackRock Inc., and BNP Paribas Arbitrage SA. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Hunter C Smith, Joseph Shulman, William T Roberts, and Yann Mazabraud.
View insider buying and selling activity for Rhythm Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Rhythm Pharmaceuticals stock?

RYTM stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Rock Springs Capital Management LP, Goldman Sachs Group Inc., Pinz Capital Management LP, Bell & Brown Wealth Advisors LLC, Primecap Management Co. CA, Dimensional Fund Advisors LP, and Renaissance Technologies LLC.
View insider buying and selling activity for Rhythm Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $3.27.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals has a market capitalization of $164.79 million and generates $3.15 million in revenue each year. The company earns $-69.61 million in net income (profit) each year or ($3.30) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

Rhythm Pharmaceuticals employs 140 workers across the globe.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at (857) 264-4280, via email at [email protected], or via fax at 857-264-4299.

This page was last updated on 5/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.